Chimerix, Inc. (NASDAQ:CMRX) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Separately, Zacks Investment Research lowered Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th.

Shares of Chimerix (NASDAQ CMRX) remained flat at $5.37 on Wednesday. 196,245 shares of the company’s stock were exchanged. The company’s market capitalization is $252.64 million. Chimerix has a 12-month low of $3.66 and a 12-month high of $6.64. The company’s 50-day moving average is $5.00 and its 200-day moving average is $5.15.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. The business had revenue of $0.68 million during the quarter, compared to analyst estimates of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. Equities research analysts anticipate that Chimerix will post ($1.63) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “ValuEngine Upgrades Chimerix, Inc. (CMRX) to “Sell”” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2017/10/11/valuengine-upgrades-chimerix-inc-cmrx-to-sell.html.

Several institutional investors and hedge funds have recently modified their holdings of CMRX. Voya Investment Management LLC grew its holdings in shares of Chimerix by 18.3% in the second quarter. Voya Investment Management LLC now owns 29,203 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 4,526 shares during the period. American International Group Inc. grew its holdings in shares of Chimerix by 7.1% in the first quarter. American International Group Inc. now owns 26,281 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 1,733 shares during the period. State of Wisconsin Investment Board bought a new stake in shares of Chimerix in the second quarter worth $185,000. The Manufacturers Life Insurance Company grew its holdings in shares of Chimerix by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 39,628 shares of the biopharmaceutical company’s stock worth $216,000 after acquiring an additional 3,042 shares during the period. Finally, Metropolitan Life Insurance Co. NY bought a new stake in shares of Chimerix in the first quarter worth $226,000. 67.53% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.